SEC Filing – Corcept Therapeutics, Incorporated

View:

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

BIRD JEFFREY W

(Last)

(First)

(Middle)

755 PAGE MILL ROAD, SUITE A-200

(Street)

PALO ALTO

943041005

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
04/14/2004

3. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series A Preferred Stock	⁽¹⁾	⁽²⁾	Common Stock	8,019	0.0000⁽³⁾	I	By Ltd Partnership (SHAI)⁽⁴⁾
Series A Preferred Stock	⁽¹⁾	⁽²⁾	Common Stock	20,304	0.0000⁽³⁾	I	By Ltd Partnership (SHQP)⁽⁵⁾
Series A Preferred Stock	⁽¹⁾	⁽²⁾	Common Stock	791,586	0.0000⁽³⁾	I	By Ltd Partnership (SHV)⁽⁶⁾
Series B Preferred Stock	⁽¹⁾	⁽²⁾	Common Stock	5,775	0.0000⁽³⁾	I	By Ltd Partnership (SHAI)⁽⁴⁾
Series B Preferred Stock	⁽¹⁾	⁽²⁾	Common Stock	14,619	0.0000⁽³⁾	I	By Ltd Partnership (SHQP)⁽⁵⁾
Series B Preferred Stock	⁽¹⁾	⁽²⁾	Common Stock	569,940	0.0000⁽³⁾	I	By Ltd Partnership (SHV)⁽⁶⁾
Series BB Preferred Stock	⁽¹⁾	⁽²⁾	Common Stock	1,228	0.0000⁽⁷⁾	I	By Ltd Partnership (SHAI)⁽⁴⁾
Series BB Preferred Stock	⁽¹⁾	⁽²⁾	Common Stock	3,109	0.0000⁽⁷⁾	I	By Ltd Partnership (SHQP)⁽⁵⁾
Series BB Preferred Stock	⁽¹⁾	⁽²⁾	Common Stock	121,780	0.0000⁽⁷⁾	I	By Ltd Partnership (SHV)⁽⁶⁾
Series C Preferred Stock	⁽¹⁾	⁽²⁾	Common Stock	7,400	0.0000⁽⁷⁾	I	By Ltd Partnership (SHAI)⁽⁴⁾
Series C Preferred Stock	⁽¹⁾	⁽²⁾	Common Stock	18,736	0.0000⁽⁷⁾	I	By Ltd Partnership (SHQP)⁽⁵⁾
Series C Preferred Stock	⁽¹⁾	⁽²⁾	Common Stock	732,882	0.0000⁽⁷⁾	I	By Ltd Partnership (SHV)⁽⁶⁾
Series C Preferred Stock	⁽¹⁾	⁽²⁾	Common Stock	3,456	0.0000⁽⁷⁾	I	By Trust⁽⁸⁾

Explanation of Responses:

1. Immediately.

2. Not applicable.

3. Each preferred share is convertible without consideration into three (3) shares of common stock.

4. Shares held by Sutter Hill Entrepreneurs Fund (AI), L.P. The reporting person is a Managing Director of the General Partner of Sutter Hill Entrepreneurs Fund (AI), L.P. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the partnership.

5. Shares held by Sutter Hill Entrepreneurs Fund (QP), L.P. The reporting person is a Managing Director of the General Partner of Sutter Hill Entrepreneurs Fund (QP), L.P. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the partnership.

6. Shares held by Sutter Hill Ventures, A California Limited Partnership. The reporting person is a Managing Director of the General Partner of Sutter Hill Ventures, A California Limited Partnership. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the partnership.

7. Each preferred share is convertible without consideration into one (1) share of common stock.

8. Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust.

Remarks:

	By: Robert Yin, by power of attorney	04/14/2004
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY


	Know all by these presents, that the undersigned hereby authorizes
David E. Sweet, Robert Yin, Patricia Tom, David L. Anderson, G. Leonard
Baker, Jr., Tench Coxe, Gregory P. Sands, James C. Gaither, James N. White, or
William H. Younger, Jr. to execute for and on behalf of the undersigned Forms
3, 4, and 5, and any Amendments thereto for Corcept Therapeutics, Incorporated
("the Company"), and cause such form(s) to be filed with the United States
Securities and Exchange Commission pursuant to Section 16(a) of the Securities
Act of 1934, relating to the undersigned's beneficial ownership of securities
in the Company.  The undersigned hereby grants to each such attorney-in-fact
full power and authority to do and perform any and every act and thing
whatsoever requisite, necessary, or proper to be done in the exercise of any of
the rights and powers herein granted, as fully to all intents and purposes as
the undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted.  The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such a capacity at the request of
the undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934.
	This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of, and transactions in, securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing delivered
to the foregoing attorneys-in-fact.
	In witness whereof, the undersigned has caused this Power of Attorney
to be executed as of this 13th day of April, 2004.




					/s/  Jeffrey W. Bird